Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) have been given a consensus rating of “Buy” by the six research firms that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $16.80.
Several brokerages recently commented on REPL. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Roth Mkm initiated coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a research note on Monday, September 16th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th.
Get Our Latest Stock Analysis on REPL
Insider Transactions at Replimune Group
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of REPL. Price T Rowe Associates Inc. MD grew its stake in Replimune Group by 12.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock valued at $53,505,000 after buying an additional 699,679 shares during the last quarter. Millennium Management LLC grew its stake in Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after buying an additional 2,656,173 shares during the last quarter. Vanguard Group Inc. grew its stake in Replimune Group by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock valued at $22,634,000 after buying an additional 32,555 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Replimune Group by 300.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock valued at $18,874,000 after buying an additional 1,679,553 shares during the last quarter. Finally, Clearbridge Investments LLC grew its stake in Replimune Group by 2.7% in the 1st quarter. Clearbridge Investments LLC now owns 277,969 shares of the company’s stock valued at $2,271,000 after buying an additional 7,274 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.
Replimune Group Stock Down 0.4 %
Shares of NASDAQ:REPL opened at $11.96 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 13.46 and a current ratio of 13.46. The company has a market cap of $817.11 million, a PE ratio of -3.66 and a beta of 1.21. Replimune Group has a 52 week low of $4.92 and a 52 week high of $15.18. The firm has a 50 day simple moving average of $10.93 and a 200 day simple moving average of $8.97.
Replimune Group (NASDAQ:REPL – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.10. As a group, research analysts expect that Replimune Group will post -3.05 earnings per share for the current year.
Replimune Group Company Profile
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Featured Articles
- Five stocks we like better than Replimune Group
- The Risks of Owning Bonds
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Overbought Stocks Explained: Should You Trade Them?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.